康哲药业(0867.HK)涨超12%创1年新高
格隆汇1月25日丨康哲药业(0867.HK)盘中拉升涨12.13%报11.46港元,股价创1年新高,暂成交1.19亿港元,市值282亿港元。公司日前公布,去年1月获Cadila Healthcare授权的德度司他片(Desidustat Tablets)获得中国国家药品监督管理局签发的药物临床试验批准,同意开展慢性肾病引起的贫血(包括透析及非透析患者)适应症的临床试验。汇证近日发研报重申康哲药业买入评级,目标价升至16.5港元;认为其强劲的销售渠道及于低线城市的渗透率有助公司保有其市占率,预期于2019-2022年间收入及利润的年复合增长率分别为7.7%及10.5%。

Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.